Bunger, DeepakRajani, AnilPatel, LavSharma, Shreekant2023-08-282023-08-282022-11Bunger Deepak, Rajani Anil, Patel Lav, Sharma Shreekant. Real-world use and acceptance of biosimilar rituximabin oncology practice in India. International Journal of Advances in Medicine. 2022 Nov; 9(11): 1096-11012349-39332349-3925http://imsear.searo.who.int/handle/123456789/225906Background: To describe the treatment patterns, patient characteristics and usage pattern of biosimilar rituximab for the treatment of Non-Hodgkin lymphomas (NHL) in India.Methods:This real-world, retrospective, analysis included adult patients receiving biosimilar rituximabbetween April 2021 and March 2022. Results:A total of 750 patients with NHL who received biosimilar rituximab were included. The most common indications reported in this analysis were diffuse large cell B-cell lymphoma [DLBCL, 64.5% (n=484)], follicular lymphoma, [FL, 23.7% (n=178)], and mantle cell lymphoma [MCL, 5.3% (n=40)]; other subtypes constituted 6.4% of the patients (n=48). The mean age of patients among DLBCL, FL and MCL was 65.5, 55.3 and 57 years, respectively. Across the lymphomas, >90% of the patients received R-chemo as first-line therapy. R-CHOP was the most common regimen across indications. Conclusions:Biosimilar rituximab-based chemotherapyis being adopted in real-world clinical practice in India for the management of patients with B-cell NHL including DLBCL, FL, MCL and other lymphomas.RituximabBiosimilarLymphomaNon-HodgkinJournal ArticleIndiaMedical Affairs, Intas Pharmaceuticals Limited, Ahmedabad, Gujarat, India